Bli medlem
Bli medlem

Du är här


Orion Oyj: Publishing of Orion Corporation's Interim Report for January-September 2016 on 25 October 2016


Publishing of Orion Corporation's Interim Report for January-September 2016 on 25 October 2016Orion will publish its Interim Report for January-September 2016 on Tuesday,
25 October 2016 approximately at 12:00 noon Finnish time (EEST). The release
and related presentation material in Finnish and in English will be available
on the Group's homepage after the

News conference for analysts and mediaA news conference for analysts and media will be held on Tuesday, 25 October
2016 at 13:30 EEST at Hotel Kämp,
address Pohjoisesplanadi 29, Helsinki. President and CEO Timo Lappalainen will
give a brief presentation in English on the financial review. Questions can
be asked after the result presentation.

Participants should be prepared to present a photo ID on request.

Live webcast and conference callA link to the live webcast will be available at Orion's

The conference call ID is 3897800 and the phone numbers to participate the
conference are:

| Finland: +358 (0)9 7479 0404 |
| Sweden: +46 (0)8 5065 3942 |
| UK: +44 (0)20 7026 5967 |
| USA: +1 719-325-2202 |
News conference recordingsA recording of the event in English and a recording of the presentation by the
President and CEO in Finnish will be available on the Orion website later the
same day.

Silent periodThe silent period preceding the publication is ongoing and continues until the

Orion Corporation

| Timo Lappalainen Jari Karlson |
|President and CEO |
| CFO |
Contact person:

Tuukka Hirvonen, Communications Manager, IR&Financial Communications
tel. +358 10 426 2721


Orion Corporation
Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical
ingredients and diagnostic tests. The company is continuously developing new
drugs and treatment methods. The core therapy areas of Orion's pharmaceutical
R&D are central nervous system (CNS) disorders, oncology and respiratory for
which Orion developes inhaled Easyhaler® pulmonary drugs.

Orion's net sales in 2015 amounted to EUR 1,016 million and the company had
about 3,400 employees. Orion's A and B shares are listed on Nasdaq Helsinki.


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Orion Oyj via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.